Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal

A merger between Liminatus Pharma LLC and special purpose acquisition company Iris Acquisition Corp. (NASDAQ:IRAA) will result in the oncology company trading on NASDAQ. The biotech, which will be renamed Liminatus Pharma Inc., is conducting a Phase II trial of a vaccine for GCC-expressing cancers. Iris’ trust holds $276 million; Liminatus also expects to receive a total of $40 million from concurrent PIPE and convertible note financings. Behind the vaccine, Liminatus hopes to bring a CAR T therapy into the clinic, and advance a preclinical CD47 inhibitor.

FDA lifted a clinical hold and cleared an IND for BEAM-201, allowing Beam Therapeutics Inc. (NASDAQ:BEAM) to proceed with a clinical study of the multiplex silenced, allogeneic CAR T therapy targeting CD7 to treat relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. The agency had placed the hold in early August. ...